Merck to expand r&d presence in China

Published: 23-Nov-2009

Merck KGaA is to invest more than Euro 150m and create more than 200 jobs in China


Merck KGaA is to invest more than Euro 150m and create more than 200 jobs in China over the next four years as it strengthens the global research and development capabilities of its Merck Serono division. The company says it will establish a global r&d centre in Beijing.

This centre in China will become one of the key r&d hubs for Merck Serono worldwide, joining operations in Germany, Switzerland and the US. It will lead drug development for local and global clinical trials in China and other Asian countries and look for partnerships with local academic institutions and companies.

Research activities in the China centre will mainly focus on biomarker research including pharmacogenomics and bioanalytics activities.

"The creation of the China r&d centre marks a new milestone in Merck Serono's commitment to China, where there is a rising demand for more healthcare options," said Elmar Schnee, executive board member with responsibility for the pharmaceuticals business sector.

Merck Serono already has some research collaborations in China and plans to develop these further by tapping into Chinese scientific expertise.

Merck Serono China currently employs more than 1,000 people across the country and offers a portfolio of innovative medicines, including the division's leading treatments for cancer (Erbitux), multiple sclerosis (Rebif), infertility (Gonal-f), endocrine and metabolic disorders (Saizen), as well as cardiometabolic diseases (Concor, Euthyrox).

  • Companies:
  • Merck Group
See more

You may also like

Research & Development

Amphista Therapeutics reaches research milestone and triggers a milestone payment from Merck

Read more
Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue degraders for oncology and immunology indications

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Research & Development

Amphista Therapeutics reaches research milestone and triggers a milestone payment from Merck

Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue degraders for oncology and immunology indications
Research & Development

Quibim partners with Merck KGaA to develop imaging-based diagnostics

Quibim and Merck KGaA have partnered to develop diagnostic tools which will fortify the implementation of personalised medicine
Sustainability

Altenex Energy advises Merck KGaA on power purchase agreement for 130 MW of new wind and solar in Spain

Deal advances Merck KGaA, Darmstadt, Germany’s climate commitments and will deliver needed renewable energy to the region
Manufacturing

MilliporeSigma invests $25m into cell culture media

The subsidiary of Merck has announced the expansion of its facility in Lenexa, Kansas, adding 98,000 sqft of lab space in the process
Manufacturing

Improving the operational efficiency of single-use assemblies in liquid bioprocessing

Merck recently announced the launch of its Ultimus Single-Use Process Container Film, which has been designed to provide extreme durability and leak resistance for the single-use assemblies used during bioprocessing liquid applications. Dr Kevin Robinson spoke to Greg Verni, Head of Single-Use and Systems, to find out more
Drug Delivery

Curia and MilliporeSigma sign deal for use of cell line for proteins and antibodies

Following this agreement, the CHOZN GS-/- cell line has been integrated into Curia’s cell line development workflow and is immediately available to Curia customers
Drug Delivery

Merck invests €290m in biosafety testing capacity

The company aims to increase its Group sales to approximately €25 billion by 2025
Subscribe now